Skip to content
Menu

BMO Capital Maintains Outperform on Disc Medicine, Raises Price Target to $120

Benzinga Newsdesk 1 month ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

BMO Capital analyst Evan David Seigerman maintains Disc Medicine (NASDAQ:IRON) with a Outperform and raises the price target from $100 to $120.

BMO Capital analyst Evan David Seigerman maintains Disc Medicine (NASDAQ:IRON) with a Outperform and raises the price target from $100 to $120.

Read at benzinga.com